

BioSpect

the business of BI

24 years of leveraging the business of Bio
www.biospectrumindia.com

Eli Lilly explores establishment of Centre of Excellence for insulin therapies in India

25 March 2025 | News

Global CEO of Eli Lilly calls on Union Minister Dr Jitendra Singh to discuss strengthening partnership



Global CEO of Eli Lilly, world's pioneer Insulin manufacturing company, David Ricks called on Union Minister of State (Independent Charge) for Science and Technology; Earth Sciences and Minister of State for PMO, Department of Atomic Energy, Department of Space, Personnel, Public Grievances and Pensions, Dr Jitendra Singh to discuss strengthening partnership, with a focus on Insulin and Non-Communicable Disease (NCD) therapies as well as biomanufacturing.

Eli Lilly, a global pharmaceutical giant headquartered in the US, has a significant presence in India through its subsidiary, Eli Lilly and Company (India) Pvt. Ltd. The company imports and markets medicines for diabetes, gastric cancer, lung cancer, breast cancer, osteoporosis, rheumatoid arthritis, and other critical diseases. Its operations also extend to Nepal, Bangladesh, and Sri Lanka through partnerships with local pharmaceutical firms. The talks also covered the establishment of a Centre of Excellence for insulin therapies, as well as clinical trials for advanced treatment options.

Eli Lilly's engagement with India comes at a time when the country is focusing on bolstering its pharmaceutical industry, not just for domestic needs but also as a global supplier. The potential establishment of a Centre of Excellence could serve as a critical step in making insulin therapies more accessible, reinforcing India's role in combating lifestyle diseases.